Address And Details

32 Old Slip , New York, NY 10005
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Goldman Sachs Multi-Manager Alternatives Fund (the Fund ) seeks long-term growth of capital. The Fund generally seeks to achieve its investment objective by allocating its assets among multiple investment managers ( Underlying Managers ) who are unaffiliated with the Investment Adviser and who employ one or more non-traditional and alternative investment strategies including, but not limited to, Equity Long Short, Dynamic Equity, Event Driven and Credit, Relative Value, Tactical Trading, and Opportunistic Fixed Income Strategies, each of which is described below. The Fund will primarily invest in a portfolio of (I) equity securities, including common and preferred stocks, convertible securities, rights and warrants, depositary receipts, real-estate investment trusts ( REITs ), pooled investment vehicles, including other investment companies, exchange-traded funds ( ETFs ), European registered investment funds( UCITS ) and private investment funds, and partnership interests, including master limited partnerships ( MLPs ); (ii) fixed income and/or floating rate securities, including debt issued by corporations, debt issued by governments (including the U.S. and foreign governments), their agencies, instrumentalities, sponsored entities, and political subdivisions, covered bonds, notes, debentures, debt participations, convertible bonds, non-investment grade securities (commonly known as junk bonds bank loans)(including senior secured loans) and other direct indebtedness; (iii) mortgage-backed and other mortgage-related securities, asset-backed securities, municipal securities, to be announced ( TBA ) securities, and custodial receipts; (iv) currencies; and (v) unregistered securities, including, for example, restricted securities eligible for resale pursuant to an exemption from registration under the Securities Act of 1933, as amended ( Securities Act ). The Fund investments may be publicly traded or privately issued or negotiated. The Fund may invest without restriction as to issuer capitalization, country, currency, maturity or credit rating. The Funds investments may include securities of U.S. and foreign issuers, including securities of issuers in emerging countries and securities denominated in a currency other than the U.S. dollar. Up to 15% of the Funds net assets may be invested in illiquid investments. The Fund does not have a target duration. The Fund will also invest in derivatives for both hedging and non-hedging purposes (although no Underlying Manager is required to hedge any of the Funds positions or to use derivatives). The Funds derivative investments may include (I) futures contracts, including futures based on equity or fixed income securities and/or equity or fixed income indices, interest rate futures, currency futures and swap futures; (ii) swaps, including equity, currency, interest rate, total return, variance and credit default swaps, and swaps on futures contracts; (iii) options, including long and short positions in call options and put options on indices, individual securities or currencies, stations and options on futures contracts; (iv) forward contracts, including forwards based on equity or fixed income securities and/or equity or fixed income indices, currency forwards, interest rate forwards, swap forwards and non-deliverable forwards; and (v) other instruments, including structured securities, exchange-traded notes, and contracts for differences ( CFDs ). As a result of the Funds use of derivatives, the Fund may also hold significant amounts of U.S. Treasuries or short-term investments, including money market funds, repurchase agreements, cash and time deposits. The Fund may use leverage (e.g., through borrowing and/or the use of derivatives). As a result, the sum of the Funds investment exposures may significantly exceed the amount of assets invested in the Fund, although these exposures may vary over time. The Fund may take long and/or short positions in a wide range of asset classes, including equities, fixed income, commodities and currencies, among others. Long positions benefit from an increase in the price of the underlying instrument or asset class, while short positions benefit from a decrease in that price.

Net Asset Value

as of 6:24 PM ET 09/17/2021

Performance

  • 1 Week
  • -0.60%
  • 1 Month
  • +0.96%
  • 3 Months
  • +2.29%
  • 1 Yr Return
  • +9.13%
  • 5 Yr Return
  • +14.30%

Equity Sector Breakdown

Finance 35.74%
Technology 13.00%
IndustrialCyclical 6.21%
NonDurables 4.50%
Services 4.33%
Health 2.50%
RetailTrade 2.38%
ConsumerDurables 1.00%
Utilities 0.51%
Energy 0.26%

Asset Allocation

Asset Type % Of Allocation
Stocks 44.62%
Other 30.37%
ForeignStocks 18.77%
Preferred 0.40%
Cash 0.00%
Bonds 0.00%
Convertible 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 30.00 K

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -0.04 -2.05 n/a
Beta 0.25 0.25 n/a
R Squared 0.66 0.63 n/a
Std Deviation 5.63 4.62 n/a
Sharpe Ratio 0.77 0.44 n/a

Purchase Information

as of 7:06 PM ET 09/16/2021
Minimum Initial $0
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +9.36%
  • +8.40%
+9.36% +8.40%
3 Year
  • +5.25%
  • +4.60%
+5.25% +4.60%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +2.36%
  • +2.06%
+2.36% +2.06%

Top 10 Holdings

Symbol Company Name % Of Assets
HYG ISHARES IBOXX HIGH YLD CORP B 3.47%
FGTXX GOLDMAN SACHS FIN SQ FD GOV F 26.90%
ASML ASML HOLDING NV 1.13%
ADI ANALOG DEVICES INC 1.12%
INFO IHS MARKIT LTD 1.12%
AON AON PLC 1.02%
WORK SLACK TECHNOLOGIES INC 1.01%
GMBE GYMBOREE HOLDING CORP 0.00%
AZN ASTRAZENECA PLC 0.85%
MXIM MAXIM INTEGRATED PRODUCTS INC 0.84%

Recent Articles from TheStreet

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Twitter Blue Lead

Twitter to Pay $810M to Settle Holder Suit Over User Engagement

Twitter's payment would settle a shareholder lawsuit that the company misled investors about its user engagement totals.

Starboard Takes Stake in CVS Health Corp.: Report

CVS to Add 25,000 Workers Ahead of Flu Season, Covid Booster Shots

Pharmacy giant CVS plans to add 25,000 ahead of flu season and coronavirus-related vaccinations.

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.

11. Colgate-Palmolive

Colgate-Palmolive Underappreciated, Deutsche Bank Says, Lifting to Buy

Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.

Watch Jim Cramer Live 9/20

Video: Jim Cramer on the Market Selloff, Evergrande, Debt Ceiling, Fed, Pfizer

Jim Cramer discusses the market selloff, Evergrande, debt ceiling talks, the upcoming Federal Reserve meeting, Pfizer and more in his latest video interview with TheStreet.

Wynn Lead

Wynn Resorts 'Worth Risk' of Macau Restrictions, Morgan Stanley Says

Wynn Resorts faces regulatory uncertainty in Macau, but Morgan Stanley says the casino operator is still 'worth the risk.'